Equity Details
Price & Market Data
Price: $1.91
Daily Change: -$0.03 / 1.57%
Daily Range: $1.89 - $1.96
Market Cap: $153,891,824
Daily Volume: 582,577
Performance Metrics
1 Week: -2.55%
1 Month: -16.59%
3 Months: -29.26%
6 Months: -12.79%
1 Year: 30.82%
YTD: 6.11%
About Protalix BioTherapeutics, Inc. (PLX)
Essential market overview for Protalix BioTherapeutics, Inc. (PLX). Current price: 1.91, daily change: -$0.03 / 1.57%. Market cap: 153,891,824. All key performance metrics for a full analysis.
Company Details
Employees: 226
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.